What is the role of ramucirumab in the treatment of non–small cell lung cancer (NSCLC)?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2.  A phase 3 trial in patients with stage IV NSCLC who had progressed during or after first-line platinum-based chemotherapy reported a 1-month survival benefit with ramucirumab in combination with docetaxel compared with docetaxel plus placebo. [177]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!